<DOC>
	<DOC>NCT01787383</DOC>
	<brief_summary>The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen compared to a sequential treatment regimen when two separate areas with AKs (one located on face/scalp and the other located on trunk/ extremities) are treated with ingenol mebutate gel</brief_summary>
	<brief_title>A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>Subjects must provide informed consent Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on face or scalp Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on trunk or extremities Subjects at least 18 years of age Female subjects must be of either: 1. Nonchildbearing potential, i.e. postmenopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or, 2. Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to trial treatment, to rule out pregnancy. Female subjects of childbearing potential must be willing to use effective contraception at trial entry and until completion. Location of the selected treatment areas: on the periorbital skin within 5 cm of an incompletely healed wound within 10 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) Prior treatment with ingenol mebutate gel on face/scalp and on trunk/extremities Lesions in the selected treatment areas that have: atypical clinical appearance (and/or, recalcitrant disease History or evidence of skin conditions other than the trial indication that would interfere with the evaluation of the trial medication Use of cosmetic or therapeutic products and procedures which could interfere with the assessments of the selected treatment areas Clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant AE or interfere with assessments of safety and efficacy during the course of the trial, as determined by the investigator's clinical judgment. Anticipated need for hospitalisation or outpatient surgery during the first 15 days after the first trial medication application. Known sensitivity or allergy to any of the ingredients in ingenol mebutate gel Presence of sunburn within the selected treatment areas Current enrolment or participation in an investigational clinical trial within 30 days of entry into this trial Subjects previously randomised in the trial Female subjects who are breastfeeding In the opinion of the investigator, the subject is unlikely to comply with the Clinical Study Protocol Prohibited Therapies and/or Medications within 2 weeks prior to Visit 1: Cosmetic or therapeutic procedures within 2 cm of the selected treatment areas Use of topical keratolytic therapeutic products within 2 cm of the selected treatment areas Use of topical medicated creams, ointments, lotions, gels, foams or sprays including topical steroids : within 2 cm of the selected treatment areas; artificial tanners: within 5 cm of the selected treatment areas Prohibited Therapies and/or Medications: within 4 weeks prior to Visit 1: Treatment with immunomodulators, cytotoxic drugs or interferon/interferon inducers Treatment with systemic medications that suppress the immune system Treatment/therapy with ultraviolet light A (UVA) or ultraviolet light B (UVB) Prohibited Therapies and/or Medications within 8 weeks prior to Visit 1: Treatment with 5fluorouracil (5FU), imiquimod, topical diclofenac sodium, or photodynamic therapy within 2 cm of the selected treatment areas. Prohibited Therapies and/or Medications within 6 months prior to Visit 1: Use of systemic retinoids or biologic/monoclonal antibody therapies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Actinic Keratosis</keyword>
	<keyword>Ingenol mebutate gel</keyword>
</DOC>